FDA Aims For Greater Role In Pharma Business Continuity Planning
Executive Summary
Legislative proposals described in the US FDA’s FY 2020 budget request justification document would give the agency more authority to oversee business continuity planning at pharmaceutical companies with the idea of preventing shortages of essential drugs.
You may also be interested in...
Coronavirus Legislation On Pharma Supply Chain Aims to Repatriate Manufacturing
But bipartisan bill only mandates a study on how the US could restore domestic manufacturing, reduce dependence on China.
A Rebuke To Pharma Globalization? Coronavirus Shows Value Of Regional Supply Chain Redundancy
As virus impedes China’s API production and spreads to other global manufacturing centers, need for robust supply chain alternatives becomes clear.
Coronavirus Not Impacting Rx Manufacturing Supply Chain – Yet
US FDA’s drug shortage team continues to check in with sponsors, but so far the infections and quarantines have not impacted drug production.